12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Igan Biosciences, Shire deal

Igan granted Shire exclusive, worldwide rights to develop and commercialize preclinical IgA protease to treat IgA nephropathy, a rare kidney disorder. Geller Biopharm Inc. advised Igan....

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >